While GLP-1s work by regulating appetite, blood sugar, and digestion, a well-balanced lifestyle with proper nutrition, exercise, and stress management can achieve even better long-term resultswithout side effects
Monotherapy reached near 10.8 percent at the top dose by week 26 against roughly 3 percent on placebo, with the usual mild appetite-agent side effects
[7] [8] This triple-receptor mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
In contrast, Ozempic and Wegovy primarily work by dulling appetite, with less emphasis on broader metabolic resilience
""Tan jab" is an unlicensed medicine and may not be safe" (Press release)
J Ethnopharmacol (2003) 87:1157